RIGEL PHARMACEUTICALS INC (RIGL)

US7665596034 - Common Stock

1.48  -0.01 (-0.67%)

After market: 1.49 +0.01 (+0.68%)

Fundamental Rating

2

RIGL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 592 industry peers in the Biotechnology industry. RIGL may be in some trouble as it scores bad on both profitability and health. RIGL is quite expensive at the moment. It does show a decent growth rate.



2

1. Profitability

1.1 Basic Checks

RIGL had negative earnings in the past year.
RIGL had a negative operating cash flow in the past year.
In the past 5 years RIGL always reported negative net income.
In the past 5 years RIGL reported 4 times negative operating cash flow.

1.2 Ratios

The Return On Assets of RIGL (-21.41%) is better than 79.59% of its industry peers.
Industry RankSector Rank
ROA -21.41%
ROE N/A
ROIC N/A
ROA(3y)-25.25%
ROA(5y)-29.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

RIGL's Gross Margin of 93.92% is amongst the best of the industry. RIGL outperforms 95.58% of its industry peers.
In the last couple of years the Gross Margin of RIGL has remained more or less at the same level.
RIGL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.8%
GM growth 5Y-1.11%

1

2. Health

2.1 Basic Checks

RIGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RIGL has been increased compared to 1 year ago.
RIGL has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, RIGL has a worse debt to assets ratio.

2.2 Solvency

RIGL has an Altman-Z score of -14.84. This is a bad value and indicates that RIGL is not financially healthy and even has some risk of bankruptcy.
RIGL has a Altman-Z score of -14.84. This is amonst the worse of the industry: RIGL underperforms 85.03% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -14.84
ROIC/WACCN/A
WACC9.64%

2.3 Liquidity

A Current Ratio of 1.86 indicates that RIGL should not have too much problems paying its short term obligations.
With a Current ratio value of 1.86, RIGL is not doing good in the industry: 80.10% of the companies in the same industry are doing better.
A Quick Ratio of 1.76 indicates that RIGL should not have too much problems paying its short term obligations.
The Quick ratio of RIGL (1.76) is worse than 79.08% of its industry peers.
Industry RankSector Rank
Current Ratio 1.86
Quick Ratio 1.76

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 55.88% over the past year.
The Revenue has decreased by -2.80% in the past year.
The Revenue has been growing by 21.30% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)55.88%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-100%
Revenue 1Y (TTM)-2.8%
Revenue growth 3Y2.48%
Revenue growth 5Y21.3%
Revenue growth Q2Q-30.2%

3.2 Future

The Earnings Per Share is expected to grow by 28.78% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 12.29% on average over the next years. This is quite good.
EPS Next Y36.54%
EPS Next 2Y38.75%
EPS Next 3Y35.59%
EPS Next 5Y28.78%
Revenue Next Year22.29%
Revenue Next 2Y20.84%
Revenue Next 3Y16.51%
Revenue Next 5Y12.29%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RIGL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RIGL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

RIGL's earnings are expected to grow with 35.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.75%
EPS Next 3Y35.59%

0

5. Dividend

5.1 Amount

RIGL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

RIGEL PHARMACEUTICALS INC

NASDAQ:RIGL (3/28/2024, 8:00:02 PM)

After market: 1.49 +0.01 (+0.68%)

1.48

-0.01 (-0.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap259.56M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.41%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 93.92%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.86
Quick Ratio 1.76
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)55.88%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y36.54%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-2.8%
Revenue growth 3Y2.48%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y